157 related articles for article (PubMed ID: 26416151)
1. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.
Sullivan RJ; Flaherty KT
Nat Rev Clin Oncol; 2015 Nov; 12(11):625-6. PubMed ID: 26416151
[No Abstract] [Full Text] [Related]
2. Pembrolizumab superior to ipilimumab in melanoma.
Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
[TBL] [Abstract][Full Text] [Related]
3. NICE guidance on pembrolizumab for advanced melanoma.
Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
[No Abstract] [Full Text] [Related]
4. Immunotherapy in advanced melanoma: a network meta-analysis.
Pyo JS; Kang G
Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
Sullivan RJ; Flaherty KT
Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for patients with advanced melanoma.
Burki TK
Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25921425
[No Abstract] [Full Text] [Related]
8. [To outwit melanoma with its own tricks].
Bischoff A
MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
[No Abstract] [Full Text] [Related]
9. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
Hamid O
Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
[No Abstract] [Full Text] [Related]
10. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
11. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract][Full Text] [Related]
12. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
13. Pembrolizumab for melanoma- safety profile and future trends.
Daud A; Nandoskar P
Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
[No Abstract] [Full Text] [Related]
14. Randomized trials in melanoma: an update.
Eggermont AM
Surg Oncol Clin N Am; 2006 Apr; 15(2):439-51. PubMed ID: 16632225
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
16. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Hersey P; Gowrishankar K
Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
[TBL] [Abstract][Full Text] [Related]
17. T-DM1 aids patients with advanced breast cancer.
Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
[No Abstract] [Full Text] [Related]
18. [ASCO highlights in the treatment of metastatic melanoma].
Hertlein A
Med Monatsschr Pharm; 2014 May; 37(5):183-4. PubMed ID: 24908933
[No Abstract] [Full Text] [Related]
19. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy of metastatic melanoma: on the road to cure.
Bhatia S; Tykodi SS; Lee SM; Thompson JA
Oncology (Williston Park); 2015 Feb; 29(2):126-35. PubMed ID: 25683834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
